Fan L, Zhang F, Xu S, Cui X, Hussain A, Fazli L, et al. Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells. Proc Natl Acad Sci U S A. 2018;115:E4584-E4593 pubmed publisher

Song Z, Li Z, Han W, Zhu C, Lou N, Li X, et al. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma. Aging (Albany NY). 2020;13:1842-1858 pubmed publisher

Lin C, Chou F, Lu J, Lin W, Truong M, Tian H, et al. Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells. Aging (Albany NY). 2020;12:17694-17712 pubmed publisher

Jiang G, Shi L, Zheng X, Zhang X, Wu K, Liu B, et al. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Aging (Albany NY). 2020;12:11466-11484 pubmed publisher

Kounatidou E, Nakjang S, McCracken S, Dehm S, Robson C, Jones D, et al. A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. Nucleic Acids Res. 2019;47:5634-5647 pubmed publisher

Cato L, De Tribolet Hardy J, Lee I, Rottenberg J, Coleman I, Melchers D, et al. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. 2019;35:401-413.e6 pubmed publisher

Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues D, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 2019;129:192-208 pubmed publisher